Uterine recurrence of acute lymphoblastic leukemia: diagnosis, treatment and literature review

Background: Extramedullary relapse of B-cell acute lymphoblastic leukaemia (B-ALL) occurs in 2–6% of cases, with the central nervous system and testes being the most commonly affected sites. Infiltration of gynaecological organs is an exceedingly rare occurrence, with the majority of documented cases pertaining to the ovary. Case: This study presents the case of a 14-year-old girl with extramedullary relapse of B-ALL in the uterus, following intensive chemotherapy and immunotherapy with inotuzumab. The patient presented with symptoms of abnormal uterine bleeding and severe pelvic pain. She was treated with surgical intervention (bilateral hysterosalpingo-oophorectomy) and subsequently received chimeric antigen receptor T-Cell (CAR-T19) therapy, yet the disease remained refractory. It is possible that CAR T-cell therapy may be more effective at penetrating extramedullary sites, although relapses can occur, in a manner similar to that observed with haematopoietic stem cell transplantation. Conclusions: Uterine relapse is an uncommon occurrence in ALL, and there is currently no established therapeutic approach. This rare presentation may be more common with newer immunotherapeutic approaches in patients with advanced disease and should be considered in the presence of metrorrhagia or pain. Although CAR T-cell therapy may be effective in extramedullary disease, hysterectomy may be a viable option in the treatment of uterine relapse in ALL to manage gynaecological symptoms and reduce tumour burden in order to achieve a complete response to systemic treatment.

Extramedullary relapse; Gynaecological organs; B-cell acute lymphoblastic leukaemia; CAR T-cell therapy; Methrorragia; Hysterectomy

[1] Rogne T, Wang R, Wang P, Deziel NC, Metayer C, Wiemels JL, et al. High ambient temperature in pregnancy and risk of childhood acute lymphoblastic leukaemia: an observational study. The Lancet Planetary Health. 2024; 8: e506–e514.

[2] Robillard DT, Kutny MA, Chewning JH, Arbuckle JL. Extramedullary relapse of acute lymphoblastic leukemia presenting as abnormal uterine bleeding: a case report. Journal of Pediatric and Adolescent Gynecology. 2017; 30: 431–434.

[3] Cecalupo AJ, Frankel LS, Sullivan MP. Pelvic and ovarian extramedullary leukemic relapse in young girls: a report of four cases and review of the literature. Cancer. 1982; 50: 587–593.

[4] Kawano N, Maeda T, Kawano S, Naghiro Y, Takami A, Tochigi T, et al. Uterine relapse of Philadelphia chromosome-negative acute lymphoblastic leukemia. Journal of Clinical and Experimental Hematopathology. 2020; 60: 103–107.

[5] Tsagkas N, Troussa A, Vorgias G, Tzaida O, Zagorianakou N, Gonidi M. Extramedullary leukemia, presenting at the cervix of the uterus. Case Reports in Obstetrics and Gynecology. 2020; 2020: 8492036.

[6] Kido A, Togashi K, Koyama T, Yamaoka T, Fujiwara T, Fujii S. Diffusely enlarged uterus: evaluation with MR imaging. Radiographics. 2003; 23: 1423–1439.

[7] Alves Viera MA, Cunha TM. Primary lymphomas of the female genital tract: imaging findings. Diagnostic and Interventional Radiology. 2014; 20: 110–115.

[8] Albano D, Bruno A, Patti C, Micci G, Midiri M, Tarella C, et al. Whole-body magnetic resonance imaging (WB-MRI) in lymphoma: state of the art. Hematological Oncology. 2020; 38: 12–21.

[9] Kwee TC, Basu S, Torigian DA, Nievelstein RA, Alavi A. Evolving importance of diffusion-weighted magnetic resonance imaging in lymphoma. PET Clinics. 2012; 7: 73–82.

[10] Ortiz-Maldonado V, Alonso-Saladrigues A, Español-Rego M, Martínez-Cibrián N, Faura A, Magnano L, et al. Results of ARI-0001 CART19 cell therapy in patients with relapsed/refractory CD19-positive acute lymphoblastic leukemia with isolated extramedullary disease. American Journal of Hematology. 2022; 97: 731–739.

[11] Sönmezer M, Sükür YE, Saçinti KG, Özkavukçu S, Kankaya D, Atabekoglu CS, et al. Safety of ovarian cryopreservation and transplantation in patients with acute: leukemia: a case series. American Journal of Obstetrics & Gynecology. 2024; 230: 79.e1–79.e10.